Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)

NCT05576077 is registered in ClinicalTrials.gov with Turnstone Biologics, Corp. as lead sponsor.

NCT NCT05576077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05576077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)
Lead sponsor
Turnstone Biologics, Corp.
Phase
Phase 1
Overall status
Terminated
Start date
January 17, 2023
Completion date
February 24, 2025
Enrollment
31 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, uveal melanoma